{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106533","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.471674+00:00","generated_at":"2026-05-17T15:28:43.462372+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Atara Q2 net income $2.4M; tab-cel BLA accepted with Jan 10, 2026 PDUFA date","bullets":["Cash, equivalents and short-term investments $22.3M at June 30, up from $13.8M at March 31.","Net income $2.4M ($0.19 diluted EPS) vs. net loss prior year; revenues $17.6M, down from $28.6M.","FDA accepted tab-cel BLA with Priority Review; PDUFA goal date January 10, 2026.","Completed transfer of substantially all tab-cel activities to Pierre Fabre; $40M milestone due on FDA approval.","Full-year 2025 operating expenses expected to decrease at least 60% vs 2024; strategic options evaluation resumed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106533","json":"https://secwatch.observer/filing/0000950170-25-106533.json","markdown":"https://secwatch.observer/filing/0000950170-25-106533.md","text":"https://secwatch.observer/filing/0000950170-25-106533.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000095017025106533/0000950170-25-106533-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000095017025106533/atra-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:28:43.462372+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}